We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

HAEMONETICS

Haemonetics Corporation’s comprehensive portfolio of devices, information management, and consulting services offers ... read more Featured Products: More products

Download Mobile App




Hypercoagulability Evaluated in New‐Onset Systemic Lupus Erythematosus Patients

By LabMedica International staff writers
Posted on 30 Dec 2019
Systemic lupus erythematosus (SLE) is an autoimmune inflammatory disease that involves T cell, B cell, and dendritic cell dysfunction, as well as antinuclear autoantibody production. More...
Several clinical and scientific studies of SLE indicate an increased risk of thrombosis in these cases.

The traditional parameters for screening coagulopathy include prothrombin time (PT) and activated partial thromboplastin time (aPTT). The thromboelastography (TEG) procedure facilitates the functional evaluation of the coagulation cascade, from clot formation to clot lysis, and provides data on the entire coagulation system.

Medical scientists at the Shanghai Jiao Tong University School of Medicine (Shanghai, China) enrolled in a study a total of 41 patients with new‐onset SLE who had not undergone treatment were enrolled, and 56 healthy individuals were included as controls. Blood samples were collected using 18G needles and vacutainer tubes containing ethylenediaminetetraacetic acid (EDTA) (for complete blood cell count) and 3.2% trisodium citrate (for TEG and coagulation analyses). Moreover, 24‐hour urine collection was performed in a clean dry container.

Complete blood counts were obtained using an automated hematology analyzer DXH800 (Beckman Coulter, Brea, CA, USA). The reference range for PLT count was 101‐320 × 109/L. Routine coagulation screening assays, including PT, aPTT, fibrinogen (Fg), thrombin time (TT), d‐dimer (DD), and fibrinogen/fibrin degradation products (FDP), were performed in all the patients using an automated coagulometer CS5100 (Sysmex Corporation, Kobe, Japan). Lupus anticoagulant (LAC) status was examined using ACL‐TOP700 (Instrumentation Laboratory, Bedford, MA, USA). Blood clot formation and stability were evaluated via TEG tests using a thromboelastography analyzer (Haemonetics Corporation, Braintree, MA, USA).

The team reported that there was a significant difference in the TEG reaction time and TEG achievement of clot firmness between the groups. Moreover, these parameters were correlated with the lupus anticoagulant levels, platelet count, 24‐hour urinary total protein quantity, and systemic lupus erythematosus disease activity index ((SLEDAI). The TEG parameters were correlated with other clinical and laboratory data, such as LAC status, PLT level, and urinary total protein (UTP) and SLEDAI values. Patients with positive LAC status, higher PLT levels, UTP >500 mg/24 hours and higher SLEDAI values are known to have a greater risk of thrombosis.

The authors concluded that they have demonstrated the prospective value of TEG in evaluating hypercoagulability in patients with SLE. The study was published on December 16, 2019 in the Journal of Clinical Laboratory Analysis.

Related Links:
Shanghai Jiao Tong University School of Medicine
Beckman Coulter
Sysmex Corporation
Instrumentation Laboratory
Haemonetics Corporation



Gold Member
Troponin T QC
Troponin T Quality Control
Serological Pipet Controller
PIPETBOY GENIUS
New
DNA/RNA Extraction/Purification Kit
Nucleic Acid Extraction or Purification Kit
New
Staining Management Software
DakoLink
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.